 CARLSBAD, Calif., Feb. 08, 2022 GLOBE NEWSWIRE -- Pardes Biosciences, Inc. NASDAQ: PRDS, a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases i.e. COVID-19, today announced that a late-breaker poster presentation sharing clinical data from the ongoing PBI-0451 Phase 1 trial will be presented at the 29th Conference On Retroviruses And Opportunistic Infections CROI 2022, to be held virtually from February 12-16, 2022. 